Clinical Trials
Clinical Trials and Research Studies
Research plays a large role in cancer care. Partnering with Iowa Oncology Research Association (IORA), UnityPoint Health – John Stoddard Cancer Center, a service of UnityPoint Health – Des Moines, is able to provide central Iowans with the opportunity to participate in over 100 national and international research studies. Through research, we have identified improved methods of treating patients. With continued investment in research, we look forward to the day when we can say we have a cure for cancer.
Clinical trials offer high-quality cancer care. Entry into a research study is always a joint decision between the physician and the patient. By looking at the pros and cons of clinical trials and your other treatment choices, you are taking an active role in a decision that affects your life. If you are interested in participating in a research study, please ask your physician to determine if there is a clinical trial appropriate for you, or call our research office at (515) 241-3305.
The IORA has clinical trials available covering all areas of cancer treatment. Areas of research include: chemotherapy, radiation therapy, immunotherapy, surgery, symptom management and cancer prevention.
Research Studies
BRAIN METASTASES
CE.7: A Phase III Trial of Stereotactic Radiosurgery Compared with Whole Brain Radiotherapy (WBRT) for 5-15 Brain Metastases (DCP) (NCT03550391)
GENETIC COUNSELING
A232301CD: AYA Access Study: An Enhanced eHealth and Chat-Bot Enabled Delivery Model for Clinical Genetic Services in Community AYA Cancer Patients (DCP) (NCT07091617)
GLIOBLASTOMA
A072201: Randomized Phase II Trial of Anti-Lag-3 and Anti-PD-1 Blockade verse SOC in Patients with Recurrent Glioblastoma (NCT06325683)
MENINGIOMA
NRG-BN003: Phase III Trial of Observation versus Irradiation for a Gross Totally Resected Grade II Meningioma (NCT03180268)
ASTROCYTOMA A072301
NCT07215910: Phase III Trial of Radiotherapy Followed by Adjuvant Temozolomide in Combination with the IDH Inhibitor Vorasidenib vs Placebo in IDH-Mutated Newly-Diagnosed Grade 3 Astrocytomas (DCP)
Methodist, Mercy, Broadlawns, Mission – WL, DT, Laurel, Ankeny, Waukee
CANCER CONTROL
A212102: Blinded Reference Set for Multicancer Early Detection Blood Tests (NCT05334069)
A222101: An Early Phase and Phase II Clinical Trial to Evaluate Ganglioside-Monosialic Acid (GM1) for Preventing Paclitaxel-Associated Neuropathy (DCP) (NCT05751668)
NRG-CC011: Cognitive Training For Cancer Related Cognitive Impairment In Breast Cancer Survivors: A Multi-Center Randomized Double-Blinded Controlled Trial (DCP) (Temp closed to Accrual) (NCT05896189)
NRG-CC015: Harnessing E-Mindfulness Approaches for Living After Breast Cancer --- HEAL-ABC (DCP) (NCT06748222)
WF2304-A172401: Complementary Options for Symptom Management in Cancer (COSMIC): Assessing Benefits and Harms of Cannabis and Cannabinoid Use Among a Cohort of Cancer Patients Treated in Community Oncology Clinics (S2013 CO-ENROLLMENT ELIGIBLE) (NCT06418204)
ER+/HER2-
NCT07391774: A Phase III Trial of Rx Therapy Guided by Genomic Risk Assessment For High Anatomic Stage ER-pos/HER2-neg Breast Cancer with RS less than or equal to 25 (RxFINE-Low) (DCP)
Methodist, Mercy, Broadlawns. Mission – Carroll, WL, DM, Laurel, Ft. Dodge, Ankeny, Waukee
HER2-
NRG-BR007: A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) (NCT04852887)
S1703: Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer (NCT03723928)
S2206: Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer (NCT06058377)
HER2+
A012303: ShortStop-HER2: Shortened Duration of Adjuvant Therapy in Patients with Early-Stage HER2+ Breast Cancer Who Achieve pCR After Neoadjuvant Chemotherapy with HER2 Blockade (DCP) (NCT06876714)
GENETIC COUNSELING
A232301CD: AYA Access Study: An Enhanced eHealth and Chat-Bot Enabled Delivery Model for Clinical Genetic Services in Community AYA Cancer Patients (DCP) (NCT07091617)
TRIPLE NEGATIVE
S2013: Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study (DCP) (Cohort 1 Closed to Accrual) (NCT04871542)
S2212: Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study (DCP) (NCT05929768)
A012103: OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy (DCP) (QOL Sub Study - Closed to Accrual) (NCT05812807)
CANCER CONTROL
A211901: Reaching RURAL Cancer Survivors who Smoke Using Text-Based Cessation Interventions (DCP) (NCT05008848)
GENETIC COUNSELING
A232301CD: AYA Access Study: An Enhanced eHealth and Chat-Bot Enabled Delivery Model for Clinical Genetic Services in Community AYA Cancer Patients (DCP) (NCT07091617)
AMPULLA OF VATER
NCT07283939: PAGODA: Randomized Trial of a Proactive Graduated Dose Modification Algorithm for FOLFOX Chemotherapy to Prevent Unplanned Delays
Methodist, Mercy, Broadlawns, Mission – DM, Laurel, Ankeny, Waukee
APPENDIX
NCT07283939: PAGODA: Randomized Trial of a Proactive Graduated Dose Modification Algorithm for FOLFOX Chemotherapy to Prevent Unplanned Delays
Methodist, Mercy, Broadlawns, Mission – DM, Laurel, Ankeny, Waukee
CANCER CONTROL
A212102: Blinded Reference Set for Multicancer Early Detection Blood Tests (DCP) (NCT05334069)
WF-1806: Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults with Colorectal Cancer: The M&M Study (Age 60-74 stratum is Closed) (DCP) (NCT03998202)
COLON
NRG-GI008: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-NORTH AMERICA) (NCT05174169)
A022101: A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur) (DCP) (NCT05673148)
WF2304-A172401: Complementary Options for Symptom Management In Cancer (COSMIC): Assessing Benefits and Harms of Cannabis and Cannabinoid Use Among a Cohort of Cancer Patients Treated in Community Oncology Clinics (S2013 CO-ENROLLMENT ELIGIBLE) (NCT06418204)
S2417CD: A Pragmatic Randomized Controlled Trial To Evaluate The Effectiveness of an Intervention called Current Together After Cancer (CTAC) to Promote Guideline-Concordant Colorectal Cancer Surveillance (NCT07018869)
A232402CD: PAGODA: Randomized Trial of a Proactive Graduated Dose Modiication Algorithm for FOLFOX Chemotherapy to Prevent Unplanned Delays (NCT07283939)
Methodist, Mercy, Broadlawns, Mission – DM, Laurel, Ankeny, Waukee
ESOPHAGEAL & GASTRIC
S2013: Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study (DCP) (COHORT 1 CLOSED) (WF-2304-A172401 CO-ENROLLMET ELIGIBLE) (NCT04871542)
A022102: Randomized Phase III Trial of mFOLFIRINOX +/- Nivolumab vs. FOLFOX +/- Nivolumab for First-Line Treatment of Metastatic HER2-Negative Gastroesophageal Adenocarcinoma (DCP) (NCT05677490)
EA2174: A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma (TEMP SUSPENDED) (NCT03604991)
S2303: Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD- L1 CPS ≥ 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE) (NCT06203600)
A232402CD: PAGODA: Randomized Trial of a Proactive Graduated Dose Modification Algorithm for FOLFOX Chemotherapy to Prevent Unplanned Delays (NCT07283939)
Methodist, Mercy, Broadlawns, Mission – DM, Laurel, Ankeny, Waukee
GENETIC COUNSELING
A232301CD: AYA Access Study: An Enhanced eHealth and Chat-Bot Enabled Delivery Model for Clinical Genetic Services in Community AYA Cancer Patients (DCP) (NCT07091617)
LIVER
NRG-GI012: Phase III Randomized Trial of IO-Based Systemic Treatment +/- Liver SBRT in Hepatocellular Cancer with Macrovascular Invasion (HELIO-RT) (DCP) (NCT07166406)
PANCREATIC
EA2185: Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers (DCP) (NCT04239573)
EA2192: APOLLO: A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRC1, BRCA2 or PALB2 Mutation (NCT04858334)
NRG-GI011: Phase III Randomized Trial Dose Escalated Radiation in Locally Advanced Pancreas Cancer (LAPC) Patients (LAP100) (DCP) (NCT06958328)
S2433: Randomized Phase III Study of Second-Line Chemotherapy with or Without Panitumumab for KRAS Wild Type, Locally Advanced or Metastatic Pancreatic Adenocarcinoma (NCT06998940)
Methodist, Mercy, Broadlawns, Mission – Carroll, WL, DM, Laurel, Ft. Dodge, Ankeny, Waukee
RECTAL
A022101: A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur) (DCP) (NCT05673148)
WF2304-A172401: Complementary Options for Symptom Management In Cancer (COSMIC): Assessing Benefits and Harms of Cannabis and Cannabinoid Use Among a Cohort of Cancer Patients Treated in Community Oncology Clinics (S2013 CO-ENROLLMENT ELIGIBLE) (NCT06418204)
S2417CD: A Pragmatic Randomized Controlled Trial to Evaluate The Effectiveness of an Intervention called Current Together After Cancer (CTAC) to Promote Guideline-Concordant Colorectal Cancer Surveillance (NCT07018869)
A232402CD: PAGODA: Randomized Trial of a Proactive Graduated Dose Modification Algorithm for FOLFOX Chemotherapy to Prevent Unplanned Delays (NCT07283939)
Methodist, Mercy, Broadlawns, Mission – DM, Laurel, Ankeny, Waukee
SMALL BOWEL
A232402CD: PAGODA: Randomized Trial of a Proactive Graduated Dose Modification Algorithm for FOLFOX Chemotherapy to Prevent Unplanned Delays (NCT07283939)
Methodist, Mercy, Broadlawns, Mission – DM, Laurel, Ankeny, Waukee
A032304: Radioligand Efficacy Comparison by Initial PSA-Response Outcome in Metastatic CRPC with Lutetium 177Lu PSMA RLT (RECIPROCAL) (NCT07200830)
A212102: Blinded Reference Set for Multicancer Early Detection Blood Tests (DCP) (NCT05334069)
BLADDER
A032103: MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer (DCP) (NCT05987241)
NRG-GU015: The Phase III Adaptive Radiation and Chemotherapy for Muscle Invasive Bladder Cancer Trial (ARCHER) (DCP) (NCT07097142)
S2427: Single Arm Phase II Study of Bladder Preservation with Immunoradiotherapy After a Clinically Meaningful Response to Neoadjuvant Therapy in Patients with Muscle Invasive Bladder Cancer (BRIGHT) (NCT07061964)
NRG-GU014: Randomized Phase II Trial of Pembrolizumab and Radiation vs. Radiation and Concurrent Chemotherapy for High-Grade T1 Bladder Cancer (PARRC Trial) (NCT06770582)
Methodist, Mercy, Broadlawns, TIC, Mission – WL, DM, Laurel, Ankeny, Waukee
KIDNEY
S1931: Phase III Trial of Immunotherapy-Based Combination Therapy With or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial) (DCP) (NCT04510597)
NRG-GU012: NCT05327686 Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)
PROSTATE
S1802: Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer (DCP) (NCT03678025)
CCTG-PR26: A Randomized Phase III Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH) (NCT06592924)
A032304: Radioligand Efficacy Comparison by Initial PSA-Response Outcome in Metastatic CRPC with Lutetium 177Lu PSMA RLT (RECIPROCAL) (NCT07200830)
Methodist
S2210: A Phase II Study of Neoadjuvant Carboplatin for Localized, High Risk Prostate Cancer with Germline BRCA1/2 Mutations (NCT05806515)
Methodist, Mercy, Mission – WL, DM, Laurel, Ankeny, Waukee
PSMA-DC: An International, Prospective, Open-label, Multi-center, Randomized Phase III Study comparing lutetium (177Lu) vipivotide tetraxetan (AAA617) versus Observation to delay castration or disease recurrence in adult male patients with prostate-specific membrane antigen (PSMA) positive Oligometastatic Prostate Cancer (OMPC) (NCT05939414)
Methodist, UCI
RARE GENITOURINARY CANCERS
A031702: A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC) (COHORTS OPEN: Cohort A (small cell carcinoma/neuroendocrine of the bladder), Cohort C (squamous cell carcinoma), Cohort D (plasmacytoid urothelial carcinoma), Cohort H (sarcomatoid urothelial carcinoma), Cohort J (non-prostate bone only metastatic GU tumors), Cohort L (urethra carcinoma) (NCT03866382)
Methodist, Mercy
A212102: Blinded Reference Set for Multicancer Early Detection Blood Tests (DCP) (NCT05334069)
Methodist, Mercy, Mission – WL, DM, Laurel, Ankeny, Waukee
CERVICAL
NRG-GY037: A Phase III Study of Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer (NCT07061977)
Methodist, Mercy, Mission – WL, DM, Laurel, Ankeny, Waukee
GENETIC COUNSELING
A232301CD: AYA Access Study: An Enhanced eHealth and Chat-Bot Enabled Delivery Model for Clinical Genetic Services in Community AYA Cancer Patients (DCP) (NCT07091617)
GERM CELL TUMORS
AGCT1531: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors (DCP) (STRATUM 2 is Temporarily Closed) (NCT03067181)
A212102: Blinded Reference Set for Multicancer Early Detection Blood Tests (DCP) (NCT05334069)
EA3132: Phase II Randomized Trial of Radiotherapy with or without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) with TP53 Sequencing (NCT02734537)
A212102: Blinded Reference Set for Multicancer Early Detection Blood Tests (DCP) (NCT05334069)
GENETIC COUNSELING
A232301CD: AYA Access Study: An Enhanced eHealth and Chat-Bot Enabled Delivery Model for Clinical Genetic Services in Community AYA Cancer Patients (DCP) (NCT07091617)
HNSCC
EA3191: A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab after Resection of Recurrent / Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features (NCT04671667)
NRG-HN009: Rand Phase II/III Trial of Radiation with High-Dose Cisplatin (100 mg/m2) Every Three Weeks vs Radiation with Low-Dose Weekly Cisplatin (40mg/m2) for Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head & Neck (TEMPORARILY CLOSED TO ACCRUAL) (NCT05050162)
EA3132: Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) with TP53 Sequencing (NCT02734537)
NRG-CC013: A Randomized, Masked, Placebo Controlled, Phase II Trial of Concurrent Chemoradiation With BMX-001 In Patients With Head And Neck Squamous Cell Carcinoma Receiving Concurrent Chemoradiation (DCP) (NCT06532279)
Nasopharyngeal
A092105: Randomized Phase 2 Study of Nivolumab and Ipilimumab with or Without Cabozantinib in Patients with Advanced Nasopharyngeal Carcinoma That Have Progressed After Platinum Treatment and Immunotherapy (NCT05904080)
SALIVARY GLAND
NRG-HN010: A Phase II Trial of HER2-Targeted Therapies for Recurrent, Metastatic or Unresectable HER2-Expressing Salivary Gland Cancers (NCT05408845)
THYROID
EA3231: A Randomized Phase III Study of BRAF-Targeted Therapy vs Cabozantinib in RAI-Refractory Differentiated Thyroid Cancer with BRAF V600Em (NCT06475989)
A212102: Blinded Reference Set for Multicancer Early Detection Blood Tests (DCP) (NCT05334069)
AMYLOIDOSIS
S2213: A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis (DCP) (NCT06022939)
CANCER CONTROL
URCC-24060: Impact of Targeted Therapy on Cancer-Related Cognitive Impairment (DCP)
CHRONIC LYMPHOCYTIC LEUKEMIA / SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL)
S1925: Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL): EVLOVE CLL/SLL Study (DCP) (NCT04269902)
CNS LYMPHOMA
A051901: Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo-MR2) Induction Followed by Lenalidomide and Nivolumab Maintenance in Primary CNS Lymphoma (NCT04609046)
FOLLICULAR LYMPHOMA
S2308: Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma (NCT06337318)
GENETIC COUNSELING
A232301CD: AYA Access Study: An Enhanced eHealth and Chat-Bot Enabled Delivery Model for Clinical Genetic Services in Community AYA Cancer Patients (DCP) (NCT07091617)
Methodist, Mercy, Broadlawns, TIC, Mission – Carroll, WL, DT, Laurel, Ft Dodge, Ankeny, Pella, Waukee
HODGKIN’S LYMPHOMA
AHOD2131: A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma (DCP) (NCT05675410)
MANTLE CELL LYMPHOMA
A052101: A Randomized Phase 3 Trial of Continuous vs. Intermittent Maintenance Therapy with Zanubrutinib as Upfront Treatment in Older Patients with Mantle Cell Lymphoma (DCP) (NCT05976763)
MULTIPLE MYELOMA (MM)
EAA181: Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation (DCP) (NCT04566328)
S2209: A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of "Intermediate Fit" Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent Maintenance (DCP) (NCT05561387)
A062102: Randomized Phase 2 Study of Iberdomide Maintenance Therapy Following Idecabtagene Vicleucel CAR-T in Multiple Myeloma Patients (NCT06179888)
MYELOMATCH
MYELOMATCH: MYELOMATCH, Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI MyeloMATCH Clinical Trials (NCT04314401)
MM1MDS-A01: A Randomized Phase II Trial of Enasidenib-Based Therapies Versus Cedazuridine-Decitabine in Higher-Risk IDH2-Mutated Myelodysplastic Syndrome: A MyeloMATCH Sub-Study (NCT06577441)
NON-HODGKIN’S LYMPHOMA
WF2304-A172401: Complementary Options for Symptom Management In Cancer (COSMIC): Assessing Benefits and Harms of Cannabis and Cannabinoid Use Among a Cohort of Cancer Patients Treated in Community Oncology Clinics (S2013 CO-ENROLLMENT ELIGIBLE) (NCT06418204)
SMOLDERING MYELOMA
EAA173: Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) (DCP) (NCT03937635)
GENETIC COUNSELING
A232301CD: AYA Access Study: An Enhanced eHealth and Chat-Bot Enabled Delivery Model for Clinical Genetic Services in Community AYA Cancer Patients (DCP) (NCT07091617)
NON-SMALL CELL
A081801: Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (DCP) (NCT04267848)
EA5182: Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (DCP) (NCT04181060)
LUNG-MAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study) (DCP) (NCT03851445)
NRG-LU008: Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer (DCP) (NCT05624996)
S1900G: A Randomized Phase II Study of Capmatinib Plus Osimertinib with or Without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study) (NCT05642572)
S1900K: A Randomized Phase II Study of Tepotinib with or Without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP SUB-STUDY) (NCT06031688)
S2013: Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study (DCP) (WF2304-A172401 CO-ENROLLMENT ELIGIBLE) (NCT04871542)
A082002: A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or Without Radiation Therapy for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer. (TEMP CLOSED AS OF 12/29/25) (NCT04929041)
Methodist, Mercy, TIC, Mission – WL, DM, Laurel, Ankeny, Waukee
CCTG-BR38: Consolidative Use of Radiotherapy to Block (CURB2) Oligoprogression in Patients with Metastatic Non-Small-Cell Lung Cancer - A Randomized Phase 3 Trial (RADIATION MUST BE DONE IN DES MOINES) (NCT06686771)
Methodist, Mercy, Mission – WL, DM, Laurel, Ankeny, Waukee
SMALL CELL
NRG-LU007: Randomized Phase II/III Trial Of Consolidation Radiation + Immuno-therapy for ES-SCLC: RAPTOR trial (NCT04402788)
S2013: Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study (DCP) (NCT04871542)
A212102: Blinded Reference Set for Multicancer Early Detection Blood Tests (DCP) (NCT05334069)
S2409: PRISM: Precision in SCLC Via a Multicohort Study: Randomized Phase II Studies Evaluating Maintenance Durvalumab with or without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC) (NCT06769126)
A021901: Phase II Trial of Lutetium Lu 177 Dotatate Versus Everolimus in Somatostatin Receptor Positive Bronchial Neuroendocrine Tumors (NCT04665739
CCTG-NE1: NET RETREAT: A Phase II Study of 177 Lutetium-DOTATATE Retreatment vs. Everolimus or Sunitinib or Cabozantinib in Metastatic/Unresectable Gastroenteropancreatic Neuroendocrine Tumours. (NCT05773274)
S2012: Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab in Patient with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC) (NCT05058651
GENETIC COUNSELING
A232301CD: AYA Access Study: An Enhanced eHealth and Chat-Bot Enabled Delivery Model for Clinical Genetic Services in Community AYA Cancer Patients (DCP) (NCT07091617)
GENETIC COUNSELING
A232301CD: AYA Access Study: An Enhanced eHealth and Chat-Bot Enabled Delivery Model for Clinical Genetic Services in Community AYA Cancer Patients (DCP) (NCT07091617)
GENETIC COUNSELING
A232301CD: AYA Access Study: An Enhanced eHealth and Chat-Bot Enabled Delivery Model for Clinical Genetic Services in Community AYA Cancer Patients (DCP) (NCT07091617)
MELANOMA
WF2304-A172401: Complementary Options for Symptom Management In Cancer (COSMIC): Assessing Benefits and Harms of Cannabis and Cannabinoid Use Among a Cohort of Cancer Patients Treated in Community Oncology Clinics (S2013 CO-ENROLLMENT ELIGIBLE) (NCT06418204)